A 19-year-old Sudanese woman, who had lived for about a decade in Ugandan refugee camps, was referred for investigation of a 12-month history of a generalised rash. Two months later, her condition had deteriorated to include cachexia and drowsiness. Despite initial negative findings on investigation, human African trypanosomiasis (HAT) was suspected, and parasites were found in a double-centrifuged sample of cerebrospinal fluid. Eflornithine, the appropriate drug for treatment of late-stage disease, was obtained through the World Health Organization. This case highlights the diagnostic and therapeutic difficulties in managing late-stage HAT in a non-endemic country.

[No Keywords available]

immunoglobulin blood level parasitology antitrypanosomal agent erythrocyte sedimentation rate refugee Trypanosoma brucei centrifugation Australia skin biopsy absence of side effects Eflornithine lethargy hemoglobin blood level Trypanosoma brucei brucei African trypanosomiasis immunofluorescence test skin pruritus protein night sweat human cachexia Refugees drowsiness microcytic anemia papule diagnostic accuracy apathy immunoglobulin Trypanosomiasis, African corticosteroid gadolinium Trypanocidal Agents electroencephalogram prurigo cerebrospinal fluid analysis neurodermatitis lichenoid hyperpigmentation ethnology Young Adult Humans weight reduction case report female nuclear magnetic resonance imaging isolation and purification Article cerebrospinal fluid fever adult protein blood level hemoglobin world health organization seizure immunoglobulin G immunoglobulin M Sudan